Publications

• MorphLink: Bridging Cell Morphological Behaviors and Molecular Dynamics in Multi-modal Spatial Omics.
  bioRxiv
  08/26/2024 Authors: Huang J; Yuan C; Jiang J; Chen J; Badve SS; Gokmen-Polar Y; Segura RL; Yan X; Lazar A; Gao J
• Triple Negative Breast Cancers: An Obsolete Entity?
  Clin Breast Cancer Volume: 24 Page(s): 1 - 6
  01/01/2024 Authors: Keskinklc M; Gkmen-Polar Y; Badve SS
• Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency.
  JCO Precis Oncol Volume: 7 Page(s): e2300197
  09/01/2023 Authors: Stecklein SR; Barlow W; Pusztai L; Timms K; Kennedy R; Logan GE; Seitz R; Badve S; Gkmen-Polar Y; Porter P
• Genome-scale metabolic modeling suggests novel molecular targets in ER-positive breast cancer
  Volume: 83
  04/01/2023 Authors: Mudge ZB; Kovacs K; Kemp ML; Badve SS; Gokmen-Polar Y
• Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model.
  Cancers (Basel) Volume: 15
  03/23/2023 Authors: Ghose S; Cho S; Ginty F; McDonough E; Davis C; Zhang Z; Mitra J; Harris AL; Thike AA; Tan PH
• A predictor of response in HER2+ breast cancer-at last!
  J Natl Cancer Inst Volume: 115 Page(s): 242 - 245
  03/09/2023 Authors: Badve SS; Gkmen-Polar Y
• The Role of ESRP1 in the Regulation of PHGDH in Estrogen Receptor-Positive Breast Cancer.
  Lab Invest Volume: 103 Page(s): 100002
  03/01/2023 Authors: Gkmen-Polar Y; Gu Y; Polar A; Gu X; Badve SS
• Targeting the Tumor-Tumor Microenvironment Crosstalk.
  Expert Opin Ther Targets Volume: 27 Page(s): 447 - 457
  01/01/2023 Authors: Badve SS; Gkmen-Polar Y
• Spatially variant immune infiltration scoring in human cancer tissues.
  NPJ Precis Oncol Volume: 6 Page(s): 60
  09/01/2022 Authors: Allam M; Hu T; Lee J; Aldrich J; Badve SS; Gkmen-Polar Y; Bhave M; Ramalingam SS; Schneider F; Coskun AF
• Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast.
  Cancers (Basel) Volume: 14
  08/13/2022 Authors: Badve SS; Cho S; Lu X; Cao S; Ghose S; Thike AA; Tan PH; Ocal IT; Generali D; Zanconati F
• Is conservative management of ductal carcinoma in situ risky?
  NPJ Breast Cancer Volume: 8 Page(s): 55
  04/28/2022 Authors: Zheng L; Gkmen-Polar Y; Badve SS
• Protein Profiling of Breast Cancer for Treatment Decision-Making.
  Am Soc Clin Oncol Educ Book Volume: 42 Page(s): 1 - 9
  04/01/2022 Authors: Badve SS; Gkmen-Polar Y
• Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type.
  Oncotarget Volume: 12 Page(s): 1178 - 1186
  06/08/2021 Authors: Padda SK; Gkmen-Polar Y; Hellyer JA; Badve SS; Singh NK; Vasista SM; Basu K; Kumar A; Wakelee HA
• Thymic Carcinomas and Second Malignancies: A Single-Center Review.
  Cancers (Basel) Volume: 13
  05/19/2021 Authors: Badve SS; Dougherty R; Balatico M; Kesler KA; Loehrer P; Gkmen-Polar Y
• Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast.
  Br J Cancer Volume: 124 Page(s): 1150 - 1159
  03/01/2021 Authors: Badve SS; Cho S; Gkmen-Polar Y; Sui Y; Chadwick C; McDonough E; Sood A; Taylor M; Zavodszky M; Tan PH
• CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer.
  Sci Rep Volume: 11 Page(s): 4691
  02/25/2021 Authors: Craven KE; Gkmen-Polar Y; Badve SS
• ColoType: a forty gene signature for consensus molecular subtyping of colorectal cancer tumors using whole-genome assay or targeted RNA-sequencing.
  Sci Rep Volume: 10 Page(s): 12123
  07/21/2020 Authors: Buechler SA; Stephens MT; Hummon AB; Ludwig K; Cannon E; Carter TC; Resnick J; Gkmen-Polar Y; Badve SS
• Is Conservative Management of Ductal Carcinoma-In-Situ Risky?
  Volume: 100 Page(s): 292 - 293
  03/01/2020 Authors: Zheng L; Gokmen-Polar Y; Badve S
• Expression of PD-L1 Family Members in Breast Cancer
  Volume: 33 Page(s): 106 - 106
  03/01/2020 Authors: Badve S; Saxena R; Gokmen-Polar Y; Yu J
• Is Conservative Management of Ductal Carcinoma-In-Situ Risky?
  Volume: 33 Page(s): 292 - 293
  03/01/2020 Authors: Zheng L; Gokmen-Polar Y; Badve S
• Expression of PD-L1 Family Members in Breast Cancer
  Volume: 100 Page(s): 106 - 106
  03/01/2020 Authors: Badve S; Saxena R; Gokmen-Polar Y; Yu J
• Molecular Pathways Associated with Recurrence of Ductal Carcinoma In Situ in Singaporeans
  Volume: 100 Page(s): 154 - 155
  03/01/2020 Authors: Gokmen-Polar Y; Thike AA; Tan PH; Gu X; Cho S; Harris A; Ginty F; Badve S
• Molecular Pathways Associated with Recurrence of Ductal Carcinoma In Situ in Singaporeans
  Volume: 33 Page(s): 154 - 155
  03/01/2020 Authors: Gokmen-Polar Y; Thike AA; Tan PH; Gu X; Cho S; Harris A; Ginty F; Badve S
• Ethnicity-dependent alternative RNA splicing variations of estrogen receptor in breast cancer
  Volume: 80
  02/01/2020 Authors: Gokmen-Polar Y; Badve SS
• Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
  J Clin Oncol Volume: 37 Page(s): 3484 - 3492
  12/20/2019 Authors: Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ
• Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer.
  JNCI Cancer Spectr Volume: 3 Page(s): pkz051
  12/01/2019 Authors: Buechler SA; Gray KP; Gkmen-Polar Y; Willis S; Thrlimann B; Kammler R; Viale G; Leyland-Jones B; Badve SS; Regan MM
• TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer: Company Matters.
  J Natl Cancer Inst Volume: 111 Page(s): 1118 - 1119
  11/01/2019 Authors: Badve SS; Gkmen-Polar Y
• Ductal carcinoma in situ of breast: update 2019.
  Pathology Volume: 51 Page(s): 563 - 569
  10/01/2019 Authors: Badve SS; Gkmen-Polar Y
• A novel role for ESRP1 in regulating proliferation in therapy-resistant ER-positive breast cancer
  Volume: 79
  07/01/2019 Authors: Gokmen-Polar Y; Gu Y; Gu X; Badve SS
• Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues.
  Sci Rep Volume: 9 Page(s): 5624
  04/04/2019 Authors: Chen Y; Shen Q; White SL; Gokmen-Polar Y; Badve S; Goodman LJ
• ColotypeR gene signature predicts response to cetuximab in colorectal cancer metastases.
  Volume: 37
  02/01/2019 Authors: Buechler SA; Gokmen-Polar Y; Badve SS
• CMS-PDX: A 20-gene genomic panel to predict consensus molecular subtypes in patient-derived xenografts (PDX) of colorectal cancer.
  Volume: 37
  02/01/2019 Authors: Buechler SA; Gokmen-Polar Y; Badve SS
• Expression score (Escore) for the prediction of likelihood of recurrence of DCIS
  Volume: 79
  02/01/2019 Authors: Badve SS; Cho S; Gokmen-Polar Y; Zavodszky M; Sui Y; Chadwick C; Tan PH; Gerdes M; Harris AL; Ginty F
• Splicing factor ESRP1 controls ER-positive breast cancer progression by altering metabolic pathway genes
  Volume: 79
  02/01/2019 Authors: Gokmen-Polar Y; Gu Y; Gu X; Badve SS
• Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways.
  EMBO Rep Volume: 20
  02/01/2019 Authors: Gkmen-Polar Y; Neelamraju Y; Goswami CP; Gu Y; Gu X; Nallamothu G; Vieth E; Janga SC; Ryan M; Badve SS
• EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer.
  Breast Volume: 43 Page(s): 74 - 80
  02/01/2019 Authors: Buechler SA; Gkmen-Polar Y; Badve SS
• EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
  Clin Breast Cancer Volume: 19 Page(s): 17 - 26.e8
  02/01/2019 Authors: Buechler SA; Gkmen-Polar Y; Badve SS
• HSF1 as a Cancer Biomarker and Therapeutic Target.
  Curr Cancer Drug Targets Volume: 19 Page(s): 515 - 524
  01/01/2019 Authors: Carpenter RL; Gkmen-Polar Y
• Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model
  Volume: 13 Page(s): S606 - S606
  10/01/2018 Authors: Padda S; Gokmen-Polar Y; Badve S; Vasista S; Basu K; Kumar A; Vali S; Abbasi T; Wakelee H
• Quantitative phosphoproteome analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor-positive breast cancer
  Volume: 78
  07/01/2018 Authors: Gokmen-Polar Y; True JD; Vieth E; Gu Y; Gu X; Qi GD; Mosley AL; Badve S
• Single-cell heterogeneity in ductal carcinoma in situ of breast.
  Mod Pathol Volume: 31 Page(s): 406 - 417
  03/01/2018 Authors: Gerdes MJ; Gkmen-Polar Y; Sui Y; Pang AS; LaPlante N; Harris AL; Tan P-H; Ginty F; Badve SS
• CIBERSORT Analysis of TCGA Identifies Subgroups with Better Outcomes in Triple Negative Breast Cancer
  Volume: 98 Page(s): 56 - 56
  03/01/2018 Authors: Craven K; Gokmen-Polar Y; Badve S
• Thymic Carcinoma-Associated Second Malignancies: A Single-Center Review
  Volume: 98 Page(s): 748 - 748
  03/01/2018 Authors: Rominger RE; Badve S; Gokmen-Polar Y
• Impact of Estrogen Receptor Variants on Allred Score and Breast Cancer Outcomes
  Volume: 98 Page(s): 63 - 64
  03/01/2018 Authors: Gokmen-Polar Y; Neelamraju Y; Buechler SA; Badve S
• Thymic Carcinoma-Associated Second Malignancies: A Single-Center Review
  Volume: 31 Page(s): 748 - 748
  03/01/2018 Authors: Rominger RE; Badve S; Gokmen-Polar Y
• CIBERSORT Analysis of TCGA Identifies Subgroups with Better Outcomes in Triple Negative Breast Cancer
  Volume: 31 Page(s): 56 - 56
  03/01/2018 Authors: Craven K; Gokmen-Polar Y; Badve S
• Impact of Estrogen Receptor Variants on Allred Score and Breast Cancer Outcomes
  Volume: 31 Page(s): 63 - 64
  03/01/2018 Authors: Gokmen-Polar Y; Neelamraju Y; Buechler SA; Badve S
• The Integrated Genomic Landscape of Thymic Epithelial Tumors.
  Cancer Cell Volume: 33 Page(s): 244 - 258.e10
  02/12/2018 Authors: Radovich M; Pickering CR; Felau I; Ha G; Zhang H; Jo H; Hoadley KA; Anur P; Zhang J; McLellan M
• ColotypeR: A tool to classify colon cancers by consensus molecular subtype and subtype-specific risk of recurrence.
  Volume: 36
  02/01/2018 Authors: Buechler SA; Badve SS; Gokmen-Polar Y; Herring E; Ludwig K; Hummon A
• Three-dimensional (3D) imaging of biomarkers in human core needle biopsies of normal and cancerous breast tissue
  Volume: 78
  02/01/2018 Authors: Chen Y; Shen Q; Goodman LJ; Gokmen-Polar Y; Badve SS
• Aggressiveness of epithelial cancers is independent of epithelial-to-mesenchymal transition
  Volume: 78
  02/01/2018 Authors: Badve SS; Neelamraju Y; Goswami CP; Gu X; Nallamothu G; Gu Y; Vieth E; Janga SC; Ryan M; Gokmen-Polar Y
• Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.
  PLoS One Volume: 13 Page(s): e0204658
  01/01/2018 Authors: Gkmen-Polar Y; True JD; Vieth E; Gu Y; Gu X; Qi GD; Mosley AL; Badve SS
• Targeting BTK family in ER plus breast cancer with Ibrutinib for personalized precision medicine: a double-edged sword
  Volume: 77
  07/01/2017 Authors: Gokmen-Polar Y; Gu X; Vieth E; Badve S
• Phosphopeptide mapping of DLC1 in ER+ breast cancer reveals AMOTL2, a key hippo pathway component, as an important target.
  Volume: 35
  05/20/2017 Authors: Gokmen-Polar Y; True JD; Vieth E; Qi GD; Mosley AL; Badve SS
• EarlyR genomic signature to predict pathological complete response following neoadjuvant anthracycline-taxane chemotherapy in estrogen-receptor positive (ER plus ) breast cancer.
  Volume: 35
  05/20/2017 Authors: Buechler SA; Badve SS; Gokmen-Polar Y
• Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG 59313).
  Volume: 35
  05/20/2017 Authors: Sharma P; Barlow WE; Godwin AK; Knight LA; Walker SM; Kennedy RD; Badve SS; Gokmen-Polar Y; Pathak HB; Isakova K
• Loss of DEEBC Expression Is Lost Early in Breast Cancer Development
  Volume: 30 Page(s): 43A - 43A
  02/01/2017 Authors: Gokmen-Polar Y; Zavodszky M; Chen X; Gu X; Kodira C; Badve S
• RespondR Signature Identifies Triple-Negative Breast Cancer Patients Who Are Likely to Be Insensitive to Taxane Treatment
  Volume: 30 Page(s): 30A - 30A
  02/01/2017 Authors: Badve S; Gokmen-Polar Y; Buechler SA
• Loss of DEEBC Expression Is Lost Early in Breast Cancer Development
  Volume: 97 Page(s): 43A - 43A
  02/01/2017 Authors: Gokmen-Polar Y; Zavodszky M; Chen X; Gu X; Kodira C; Badve S
• Impact of heterogeneity of DCIS on immune cell infiltrations
  Volume: 77
  02/01/2017 Authors: Badve S; Gokmen-Polar Y; Harris AL; Sui Y; Sevinsky C; Santamaria-Pang A; Ginty F; Tan PH; Gerdes MJ
• Thymic Carcinoma Histology and Prognosis- A Single-Center Review
  Volume: 30 Page(s): 492A - 492A
  02/01/2017 Authors: Rominger RE; Balatico MA; Gokmen-Polar Y; Badve S
• Thymic Carcinoma Histology and Prognosis- A Single-Center Review
  Volume: 97 Page(s): 492A - 492A
  02/01/2017 Authors: Rominger RE; Balatico MA; Gokmen-Polar Y; Badve S
• RespondR Signature Identifies Triple-Negative Breast Cancer Patients Who Are Likely to Be Insensitive to Taxane Treatment
  Volume: 97 Page(s): 30A - 30A
  02/01/2017 Authors: Badve S; Gokmen-Polar Y; Buechler SA
• Upregulation of HSF1 in estrogen receptor positive breast cancer.
  Oncotarget Volume: 7 Page(s): 84239 - 84245
  12/20/2016 Authors: Gkmen-Polar Y; Badve S
• RespondR signature to predict response in TNBC patients treated with adjuvant taxane based chemotherapy in TCGA dataset.
  Volume: 34
  05/20/2016 Authors: Buechler SA; Gokmen-Polar Y; Badve SS
• RespondR signature to predict potential alternative therapies for taxane resistant triple-negative breast cancer patients.
  Volume: 34
  05/20/2016 Authors: Buechler SA; Gokmen-Polar Y; Badve SS
• NUT Midline Carcinoma Masquerading As a Thymic Carcinoma.
  J Clin Oncol Volume: 34 Page(s): e126 - e129
  05/10/2016 Authors: Gkmen-Polar Y; Kesler K; Loehrer PJ; Badve S
• LINC00478: A novel tumor suppressor in breast cancer
  Volume: 76
  02/15/2016 Authors: Gokmen-Polar Y; Zavodszky M; Chen X; Gu X; Kodira C; Badve S
• Co-Amplification of Chromosome 17 Genes Impacts HER2 Scoring
  Volume: 29 Page(s): 31A - 31A
  02/01/2016 Authors: Badve S; Gokmen-Polar Y
• Loss of LINC00478 Expression Is Associated with Development of Nodal Metastasis in ER plus Breast Cancer
  Volume: 96 Page(s): 43A - 43A
  02/01/2016 Authors: Gokmen-Polar Y; Zavodszky M; Chen X; Gu X; Kodira C; Badve S
• Loss of LINC00478 Expression Is Associated with Development of Nodal Metastasis in ER plus Breast Cancer
  Volume: 29 Page(s): 43A - 43A
  02/01/2016 Authors: Gokmen-Polar Y; Zavodszky M; Chen X; Gu X; Kodira C; Badve S
• Co-Amplification of Chromosome 17 Genes Impacts HER2 Scoring
  Volume: 96 Page(s): 31A - 31A
  02/01/2016 Authors: Badve S; Gokmen-Polar Y
• Identification of novel immunomodulatory tumor biology through comprehensive characterization of a metastases-specific epigenome in patients with metachronous primary and metastatic urothelial carcinoma (UC) tumor pairs.
  Volume: 34
  01/10/2016 Authors: Hahn NM; Cramer HM; Badve SS; Cheng L; Gokmen-Polar Y; Miller DF; Buechlein A; Rusch DB; Fang F; Frankhouser D
• Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation.
  Mod Pathol Volume: 28 Page(s): 1415 - 1427
  11/01/2015 Authors: Mneimneh WS; Gkmen-Polar Y; Kesler KA; Loehrer PJ; Badve S
• Breast cancer prognostic markers: an overview of a changing menu.
  MLO Med Lab Obs Volume: 47 Page(s): 8 - 13
  10/01/2015 Authors: Gkmen-Polar Y; Badve S
• Tumor Heterogeneity in Breast Cancer.
  Adv Anat Pathol Volume: 22 Page(s): 294 - 302
  09/01/2015 Authors: Badve S; Gkmen-Polar Y
• Single-cell screening and quantification of transcripts in cancer tissues by second-harmonic generation microscopy.
  J Biomed Opt Volume: 20 Page(s): 096016
  09/01/2015 Authors: Liu J; Damayanti NP; Cho I-H; Polar Y; Badve S; Irudayaraj JMK
• Novel DNA methylation therapeutic targets in urothelial carcinoma (UC) from patients with paired metachronous primary and metastatic tumors
  Volume: 51 Page(s): S529 - S529
  09/01/2015 Authors: Hahn N; Cramer H; Badve S; Cheng L; Gokmen-Polar Y; Miller D; Buechlein A; Rusch D; Fang F; Frankhouser D
• RespondR: A genomic score to predict the responsiveness of triple-negative breast cancer patients to chemotherapy
  Volume: 33
  05/20/2015 Authors: Buechler S; Gokmen-Polar Y; Badve SS
• Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer.
  Mod Pathol Volume: 28 Page(s): 677 - 685
  05/01/2015 Authors: Gkmen-Polar Y; Neelamraju Y; Goswami CP; Gu X; Nallamothu G; Janga SC; Badve S
• Differential expression of innate and adaptive immune responses in TNBC outcome
  Volume: 75
  05/01/2015 Authors: Gokmen-Polar Y; Lai X; Badve S
• ESRP1 adds sp(l)ice to endocrine resistance
  Volume: 75
  05/01/2015 Authors: Gokmen-Polar Y; Neelamraju Y; Goswami CP; Nakshatri H; Janga SC; Badve S
• Prognostic impact of HOTAIR expression is restricted to ER-negative breast cancers.
  Sci Rep Volume: 5 Page(s): 8765
  03/05/2015 Authors: Gkmen-Polar Y; Vladislav IT; Neelamraju Y; Janga SC; Badve S
• Role of lncRNAs in health and disease-size and shape matter.
  Brief Funct Genomics Volume: 14 Page(s): 115 - 129
  03/01/2015 Authors: Mohanty V; Gkmen-Polar Y; Badve S; Janga SC
• Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
  J Neurooncol Volume: 122 Page(s): 205 - 216
  03/01/2015 Authors: Duchnowska R; Jassem J; Goswami CP; Dundar M; Gkmen-Polar Y; Li L; Woditschka S; Biernat W; Sosiska-Mielcarek K; Czartoryska-Arukowicz B
• NUT midline carcinomas in the thymic region.
  Mod Pathol Volume: 27 Page(s): 1649 - 1656
  12/01/2014 Authors: Gkmen-Polar Y; Cano OD; Kesler KA; Loehrer PJ; Badve S
• Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines.
  Clin Exp Metastasis Volume: 31 Page(s): 771 - 786
  10/01/2014 Authors: Marino N; Collins JW; Shen C; Caplen NJ; Merchant AS; Gkmen-Polar Y; Goswami CP; Hoshino T; Qian Y; Sledge GW
• Splicing factors ESRP1/ESRP2 as regulators of endocrine resistance in breast cancer
  Volume: 74
  10/01/2014 Authors: Gokmen-Polar Y; Nellamraju Y; Gu X; Janga SC; Badve SS
• DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer.
  J Natl Cancer Inst Volume: 106
  07/01/2014 Authors: Woditschka S; Evans L; Duchnowska R; Reed LT; Palmieri D; Qian Y; Badve S; Sledge G; Gril B; Aladjem MI
• The prognostic value of architectural patterns in a study of 37 type AB thymomas.
  Mod Pathol Volume: 27 Page(s): 863 - 868
  06/01/2014 Authors: Vladislav IT; Gkmen-Polar Y; Kesler KA; Loehrer PJ; Badve S
• INDUCT: A risk score to predict relapse in estrogen-receptor-positive breast cancer.
  Volume: 32
  05/20/2014 Authors: Buechler S; Badve SS; Gokmen-Polar Y
• Prognostic ability of CD44 expression in ER-positive breast cancer.
  Volume: 32
  05/20/2014 Authors: Gokmen-Polar Y; Badve SS
• The Prognostic Value of Architectural Patterns in a Study of 41 Type AB Thymomas
  Volume: 27 Page(s): 497A - 498A
  02/01/2014 Authors: Vladislav IT; Gokmen-Polar Y; Kesler KA; Loehrer PJ; Badve S
• Type B Thymomas - Relevance of Current Subclassification
  Volume: 27 Page(s): 478A - 478A
  02/01/2014 Authors: Gokmen-Polar Y; Lu W; Kesler K; Loehrer PJ; Badve S
• HOTAIR Expression in Breast Cancer and Nodal Metastases
  Volume: 27 Page(s): 50A - 50A
  02/01/2014 Authors: Gokmen-Polar Y; Valdislav IT; Sirimalle U; Badve S
• SF3B1 and SF3B3 Expression in Tamoxifen Resistance
  Volume: 27 Page(s): 50A - 50A
  02/01/2014 Authors: Gokmen-Polar Y; Nellamraju Y; Goswami CP; Gu X; Janga SC; Badve S
• Type B Thymomas - Relevance of Current Subclassification
  Volume: 94 Page(s): 478A - 478A
  02/01/2014 Authors: Gokmen-Polar Y; Lu W; Kesler K; Loehrer PJ; Badve S
• The Prognostic Value of Architectural Patterns in a Study of 41 Type AB Thymomas
  Volume: 94 Page(s): 497A - 498A
  02/01/2014 Authors: Vladislav IT; Gokmen-Polar Y; Kesler KA; Loehrer PJ; Badve S
• HOTAIR Expression in Breast Cancer and Nodal Metastases
  Volume: 94 Page(s): 50A - 50A
  02/01/2014 Authors: Gokmen-Polar Y; Valdislav IT; Sirimalle U; Badve S
• SF3B1 and SF3B3 Expression in Tamoxifen Resistance
  Volume: 94 Page(s): 50A - 50A
  02/01/2014 Authors: Gokmen-Polar Y; Nellamraju Y; Goswami CP; Gu X; Janga SC; Badve S
• Multiplexed protein analysis.
  Sci Transl Med Volume: 6 Page(s): 219fs3
  01/15/2014 Authors: Gkmen-Polar Y; Badve S
• Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer.
  J Cancer Volume: 5 Page(s): 633 - 645
  01/01/2014 Authors: Gkmen-Polar Y; Goswami CP; Toroni RA; Sanders KL; Mehta R; Sirimalle U; Tanasa B; Shen C; Li L; Ivan M
• ESRP1 and ESRP2 expression in tamoxifen resistance
  Volume: 73
  12/15/2013 Authors: Goekmen-Polar Y; Goswami CP; Gu X; Nakshatri H; Badve S
• FOXP3 expression and nodal metastasis of breast cancer.
  Cell Oncol (Dordr) Volume: 36 Page(s): 405 - 409
  10/01/2013 Authors: Gkmen-Polar Y; Thorat MA; Sojitra P; Saxena R; Badve S
• A GENE SIGNATURE TO DISTINGUISH THYMIC CARCINOMA FROM THYMOMA
  Volume: 8 Page(s): 36 - 37
  09/01/2013 Authors: Goekmen-Polar Y; Cook R; Wilkinson J; Maetzold D; Stone J; Oelschlager K; Lu W; Vladislav I; Kesler K; Loehrer P
• PRECLINICAL MODELS FOR THYMIC TUMORS
  Volume: 8 Page(s): 7 - 8
  09/01/2013 Authors: Goekmen-Polar Y
• The role of histology in predicting recurrence of type A thymomas: a clinicopathologic correlation of 23 cases.
  Mod Pathol Volume: 26 Page(s): 1059 - 1064
  08/01/2013 Authors: Vladislav IT; Gkmen-Polar Y; Kesler KA; Loehrer PJ; Badve S
• Counterpoint: cancer stem cells: nonbelievers' viewpoint.
  Clin Chem Volume: 59 Page(s): 208 - 210
  01/01/2013 Authors: Gkmen-Polar Y; Badve SS
• A gene signature to determine metastatic behavior in thymomas.
  PLoS One Volume: 8 Page(s): e66047
  01/01/2013 Authors: Gkmen-Polar Y; Cook RW; Goswami CP; Wilkinson J; Maetzold D; Stone JF; Oelschlager KM; Vladislav IT; Shirar KL; Kesler KA
• Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
  Breast Cancer Res Treat Volume: 136 Page(s): 673 - 682
  12/01/2012 Authors: Gkmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
• A 19-GENE PROGNOSTIC GEP SIGNATURE TO DETERMINE METASTATIC RISK ASSOCIATED WITH THYMOMAS
  Volume: 7 Page(s): S422 - S422
  11/01/2012 Authors: Gokmen-Polar Y; Cook RW; Goswami CP; Oelschlager KM; Maetzold D; Stone J; Wilkinson J; Vladislav IT; Shirar KL; Kesler KA
• Establishment and characterization of a novel cell line derived from human thymoma AB tumor.
  Lab Invest Volume: 92 Page(s): 1564 - 1573
  11/01/2012 Authors: Gkmen-Polar Y; Sanders KL; Goswami CP; Cano OD; Zaheer NA; Jain RK; Kesler KA; Nelson RP; Vance GH; Smith D
• A 19-gene prognostic GEP signature to determine metastatic risk associated with thymomas
  Volume: 30
  10/20/2012 Authors: Gokmen-Polar Y; Goswami CP; Cook RW; Oelschlager KM; Maetzold D; Vladislav IT; Shirar KL; Kesler K; Loehrer PJ; Badve SS
• Breast cancer prognostic markers: where are we now?
  MLO Med Lab Obs Volume: 44 Page(s): 22 - 25
  09/01/2012 Authors: Gkmen-Polar Y; Badve S
• In silico identification of an epithelial core signature in human tumors
  Volume: 30
  05/20/2012 Authors: Goswami CP; Cano OD; Gokmen-Polar Y; Badve SS
• A 19-gene prognostic GEP signature (DecisionDx-Thymoma) to determine metastatic risk associated with thymomas.
  Volume: 30
  05/20/2012 Authors: Gokmen-Polar Y; Goswami CP; Cook RW; Oelschlager KM; Maetzold D; Vladislav IT; Shirar KL; Kesler K; Loehrer PJ; Badve SS
• 13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer
  Volume: 30
  05/20/2012 Authors: Duchnowska R; Jassem J; Goswami CP; Gokmen-Polar Y; Li L; Thorat MA; Flores N; Hua E; Woditschka S; Palmieri D
• Identification of transcriptional regulatory motifs that control gene expression in premenopausal women with previous history of breast cancer
  Volume: 72
  04/15/2012 Authors: Cano OD; Gokmen-Polar Y; Chirayu G; Li L; Sirimalle U; Gu X; Nakshatri H; Badve S
• Molecular profiling assays in breast cancer: are we ready for prime time?
  Oncology (Williston Park) Volume: 26 Page(s): 350 - 361
  04/01/2012 Authors: Gkmen-Polar Y; Badve S
• Extrathoracic metastases of thymic origin: a review of 35 cases.
  Mod Pathol Volume: 25 Page(s): 370 - 377
  03/01/2012 Authors: Vladislav T; Jain RK; Alvarez R; Mehta RJ; Gkmen-Polar Y; Kesler KA; Henley JD; Loehrer PJ; Badve S
• Mixed Small Cell Undifferentiated Squamous Cell Carcinoma of the Thymus - A Clinicopathologic Study of 10 Cases
  Volume: 25 Page(s): 472A - 472A
  02/01/2012 Authors: Badve S; Cano O; Gokmen-Polar Y; Kesler K; Loehrer P; Badve S
• Mixed Small Cell Undifferentiated Squamous Cell Carcinoma of the Thymus - Clinicopathologic Study of 10 Cases
  Volume: 92 Page(s): 472A - 472A
  02/01/2012 Authors: Badve S; Cano O; Gokmen-Polar Y; Kesler K; Loehrer P; Badve S
• Molecular analysis of thymoma.
  PLoS One Volume: 7 Page(s): e42669
  01/01/2012 Authors: Badve S; Goswami C; Gkmen-Polar Y; Nelson RP; Henley J; Miller N; Zaheer NA; Sledge GW; Li L; Kesler KA
• Gene Expression Analysis of Resistance to Bevacizumab in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer.
  Volume: 71
  12/15/2011 Authors: Gokmen-Polar Y; Toroni RA; Goswami C; Sanders KL; Mehta R; Sirimalle U; Tanasa B; Shen C; Li L; Ivan M
• Gene Profiling of Whole Blood May Identify Patients with BRCA Mutations.
  Volume: 71
  12/15/2011 Authors: Mina LA; Gokmen-Polar Y; Goswami C; Storniolo AM; Li L; Badve S; Sledge GW
• Bevacizumab Treatment Alters Intrinsic Subtypes in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer.
  Volume: 71
  12/15/2011 Authors: Gokmen-Polar Y; Toroni RA; Goswami C; Sanders KL; Sirimalle U; Mehta R; Li L; Ivan M; Badve S; Sledge GW
• Biomarkers for breast cancer stem cells: the challenges ahead.
  Biomark Med Volume: 5 Page(s): 661 - 671
  10/01/2011 Authors: Gkmen-Polar Y; Nakshatri H; Badve S
• Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
  Breast Cancer Res Treat Volume: 127 Page(s): 375 - 384
  06/01/2011 Authors: Gkmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
• RAD51 and brain metastases (BM) in patients (pts) with HER2+breast cancer
  Volume: 29
  05/20/2011 Authors: Duchnowska R; Jassem J; Szutowicz E; Biernat W; Jankowski T; Och W; Staszkiewicz R; Chudzik M; Rogowski W; Flores N
• In silico analysis of angiogenesis pathway as a prognostic tool in breast cancer
  Volume: 71
  04/15/2011 Authors: Mehta RJ; Jain RK; Gokmen-Polar Y; Badve S
• Study of Concordance between RT-PCR and Immunohistochemical Testing of Hormone Receptor and HER2 Status in Breast Cancer Specimens.
  Volume: 24 Page(s): 54A - 54A
  02/01/2011 Authors: Mehta R; Jain RK; Sojitra PM; Gokmen-Polar Y; Badve S
• Study of Concordance between RT-PCR and Immunohistochemical Testing of Hormone Receptor and HER2 Status in Breast Cancer Specimens
  Volume: 91 Page(s): 54A - 54A
  02/01/2011 Authors: Mehta R; Jain RK; Sojitra PM; Gokmen-Polar Y; Badve S
• Tumor marker assessment: points to ponder.
  Cancer Biol Ther Volume: 11 Page(s): 284 - 286
  01/15/2011 Authors: Gkmen-Polar Y; Badve S
• Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.
  Breast Cancer Res Treat Volume: 124 Page(s): 327 - 335
  11/01/2010 Authors: Gkmen-Polar Y; Mehta R; Tuzmen S; Mousses S; Thorat MA; Sanders KL; Turbin D; Leung S; Huntsman DG; Sledge GW
• Promise of computational systems biology for cancer clinical trials: the voyage to be realized?
  Per Med Volume: 7 Page(s): 129 - 131
  03/01/2010 Authors: Gkmen-Polar Y; Badve S
• Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer
  Volume: 69 Page(s): 210S - 211S
  01/15/2009 Authors: Gokmen-Polar Y; Toroni RA; Badve S; Bruckheimer E; Kinch MS; Miller KD
• Redefining the target again: chemotherapeutics as vascular disrupting agents?
  Cancer Cell Volume: 14 Page(s): 195 - 196
  09/09/2008 Authors: Gokmen-Polar Y; Miller KD
• 2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells.
  Cancer Res Volume: 67 Page(s): 702 - 708
  01/15/2007 Authors: Bhati R; Gkmen-Polar Y; Sledge GW; Fan C; Nakshatri H; Ketelsen D; Borchers CH; Dial MJ; Patterson C; Klauber-DeMore N
• A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells.
  Proteomics Clin Appl Volume: 1 Page(s): 18 - 31
  01/01/2007 Authors: Brown DPG; Gkmen-Polar Y; Jiang L; Tan J; Ringham H; Janecki DJ; Qi G; Witzmann FA; Sledge GW; Wang M
• Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.
  Prostate Volume: 66 Page(s): 1498 - 1511
  10/01/2006 Authors: Shanmugam R; Jayaprakasan V; Gokmen-Polar Y; Kelich S; Miller KD; Yip-Schneider M; Cheng L; Bhat-Nakshatri P; Sledge GW; Nakshatri H
• Protein kinase C-beta as a therapeutic target in breast cancer.
  Semin Oncol Volume: 33 Page(s): S15 - S18
  06/01/2006 Authors: Sledge GW; Gkmen-Polar Y
• 2-Methoxyestradiol-resistant cancer cells overexpress functional laminin alpha 4
  Volume: 66
  04/01/2006 Authors: Gokmen-Polar Y; Sanders KL; Jones JCR; Nakshatri H; Sledge GW
• beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.
  Cancer Res Volume: 65 Page(s): 9406 - 9414
  10/15/2005 Authors: Gkmen-Polar Y; Escuin D; Walls CD; Soule SE; Wang Y; Sanders KL; Lavallee TM; Wang M; Guenther BD; Giannakakou P
• Protein kinase Ciota is required for Ras transformation and colon carcinogenesis in vivo.
  J Cell Biol Volume: 164 Page(s): 797 - 802
  03/15/2004 Authors: Murray NR; Jamieson L; Yu W; Zhang J; Gkmen-Polar Y; Sier D; Anastasiadis P; Gatalica Z; Thompson EA; Fields AP
• EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
  Cancer Res Volume: 63 Page(s): 3425 - 3429
  06/15/2003 Authors: Lu M; Miller KD; Gokmen-Polar Y; Jeng M-H; Kinch MS
• Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.
  Cancer Res Volume: 61 Page(s): 1375 - 1381
  02/15/2001 Authors: Gkmen-Polar Y; Murray NR; Velasco MA; Gatalica Z; Fields AP
• Mapping of a molecular determinant for protein kinase C betaII isozyme function.
  J Biol Chem Volume: 273 Page(s): 20261 - 20266
  08/07/1998 Authors: Gkmen-Polar Y; Fields AP
• Wortmannin converts insulin but not oxytocin from an antilipolytic to a lipolytic agent in the presence of forskolin.
  Metabolism Volume: 46 Page(s): 62 - 66
  01/01/1997 Authors: Fain JN; Gokmen-Polar Y; Bahouth SW
• Mutations associated with hemophilia B in Turkish patients.
  Hum Mutat Volume: 10 Page(s): 76 - 79
  01/01/1997 Authors: Calayan SH; Gkmen Y; Aktulu G; Grgey A; Sommer SS
• Enhanced desensitization and phosphorylation of the beta 1-adrenergic receptor in rat adipocytes by peroxovanadate.
  Mol Pharmacol Volume: 49 Page(s): 1049 - 1057
  06/01/1996 Authors: Bahouth SW; Gokmen-Polar Y; Coronel EC; Fain JN
• Inhibition by NMDA of carbachol-stimulated inositol tetrakisphosphate accumulation in rat brain cortical slices.
  Neuropharmacology Volume: 35 Page(s): 415 - 421
  04/01/1996 Authors: Myles ME; Gokmen-Polar Y; Fain JN
• Insulin sensitizes beta-agonist and forskolin-stimulated lipolysis to inhibition by 2',5'-dideoxyadenosine.
  Am J Physiol Volume: 270 Page(s): C562 - C569
  02/01/1996 Authors: Gokmen-Polar Y; Coronel EC; Bahouth SW; Fain JN
• Inhibition by veratridine of carbachol-stimulated inositol tetrakisphosphate accumulation in rat brain cortical slices.
  Neurochem Res Volume: 20 Page(s): 1057 - 1064
  09/01/1995 Authors: Myles ME; Gokmen-Polar Y; Fain JN
• Polymorphisms associated with the FVIII and FIX genes in the Turkish population.
  Haemophilia Volume: 1 Page(s): 184 - 189
  07/01/1995 Authors: Calayan SH; Gkmen Y; Kirdar B